Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical firm NeurogesX has completed a $25 million private placement of its common stock to support the development of its late stage portfolio of novel pain management therapies.
Subscribe to our email newsletter
On December 26, 2007, the company entered into a securities purchase agreement in connection with a private placement to a group of institutional accredited investors.
In the closings, which occurred on December 26, 2007 and January 3, 2008 the company received approximately $25 million in gross proceeds from the sale of four million shares of its common stock at a purchase price of $6.18 per share, and the issuance of five-year warrants to purchase 1.21 million additional shares of common stock at an exercise price of $8.034 per share. The warrants were purchased at a price per underlying share of $0.125.
The financing was led by SV Life Sciences, a life sciences-focused venture capital adviser and manager. Other participating investors include Deerfield Management and Wasatch Advisors, and its private equity affiliate, Cross Creek Capital.
Pacific Growth Equities served as the exclusive placement agent for the transaction.